A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis

Change From Screening in Serum Albumin Levels at Week 4

Time Frame: Screening, Week 4

Change from screening (the last test prior to the first study medication application) in serum albumin levels at week 4 were reported.

Change From Screening in Serum Albumin Levels at Week 12

Time Frame: Screening, Week 12

Change from screening (the last test prior to the first study medication application) in serum albumin levels at week 12 were reported.

Change From Screening in Serum Albumin Levels at Week 26

Time Frame: Screening, Week 26

Change from screening (the last test prior to the first study medication application) in serum albumin levels at week 26 were reported.

Change From Screening in Serum Albumin Levels at Week 30 (Follow-up)

Time Frame: Screening, Week 30 (Follow-up)

Change from screening (the last test prior to the first study medication application) in serum albumin levels at week 30 were reported.

Change From Screening in Urine Calcium/Creatinine Ratio at Week 30 (Follow-up)

Time Frame: Screening, Week 30 (Follow-up)

Change from screening (the last test prior to the first study medication application) in urine calcium/creatinine ratio at week 30 were reported.

Change From Screening in Serum Albumin Levels at Week 8

Time Frame: Screening, Week 8

Change from screening (the last test prior to the first study medication application) in serum albumin levels at week 8 were reported.

Change From Screening in Urine Calcium/Creatinine Ratio at Week 26

Time Frame: Screening, Week 26

Change from screening (the last test prior to the first study medication application) in urine calcium/creatinine ratio at week 26 were reported.

Change From Screening in Serum Albumin Levels at Week 20

Time Frame: Screening, Week 20

Change from screening (the last test prior to the first study medication application) in serum albumin levels at week 20 were reported.

Change From Screening in Serum Phosphate Levels at Week 12

Time Frame: Screening, Week 12

Change from screening (the last test prior to the first study medication application) in serum phosphate levels at week 12 were reported.

Change From Screening in Serum Parathyroid Hormone Levels at Week 26

Time Frame: Screening, Week 26

Change from screening (the last test prior to the first study medication application) in serum PTH levels at week 26 were reported.

Change From Screening in Serum Phosphate Levels at Week 4

Time Frame: Screening, Week 4

Change from screening (the last test prior to the first study medication application) in serum phosphate levels at week 4 were reported.

Change From Screening in Serum Phosphate Levels at Week 20

Time Frame: Screening, Week 20

Change from screening (the last test prior to the first study medication application) in serum phosphate levels at week 20 were reported.

Change From Screening in Serum Phosphate Levels at Week 26

Time Frame: Screening, Week 26

Change from screening (the last test prior to the first study medication application) in serum phosphate levels at week 26 were reported.

Change From Screening in Serum Phosphate Levels at Week 30 (Follow-up)

Time Frame: Screening, Week 30 (Follow-up)

Change from screening (the last test prior to the first study medication application) in serum phosphate levels at week 30 were reported.

Change From Screening in Serum Parathyroid Hormone Levels at Week 8

Time Frame: Screening, Week 8

Change from screening (the last test prior to the first study medication application) in serum PTH levels at week 8 were reported.

Change From Screening in Serum Parathyroid Hormone Levels at Week 12

Time Frame: Screening, Week 12

Change from screening (the last test prior to the first study medication application) in serum PTH levels at week 12 were reported.

Change From Screening in Urine Calcium/Creatinine Ratio at Week 12

Time Frame: Screening, Week 12

Change from screening (the last test prior to the first study medication application) in urine calcium/creatinine ratio at week 12 were reported.

Change From Screening in Serum Parathyroid Hormone (PTH) Levels at Week 4

Time Frame: Screening, Week 4

Change from screening (the last test prior to the first study medication application) in serum PTH levels at week 4 were reported.

Change From Screening in Serum Parathyroid Hormone Levels at Week 20

Time Frame: Screening, Week 20

Change from screening (the last test prior to the first study medication application) in serum PTH levels at week 20 were reported.

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Time Frame: Up to Week 30

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with an onset date on or after the first application of the study drug.

Change From Screening in Serum Parathyroid Hormone Levels at Week 30 (Follow-up)

Time Frame: Screening, Week 30 (Follow-up)

Change from screening (the last test prior to the first study medication application) in serum PTH levels at week 30 were reported.